Effects of Yunke (technetium-99 conjugated with methylene diphosphonate; 99Tc-MDP) and/or colloidal chromic phosphate phosphonium-32, alone and in combination, in rats with adjuvant arthritis

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 1, 2008, Pages 23-28

  Wang, Liming ^a   Gu, Qiangrong ^a   Xu, Yan ^a   Li, Shaohua ^a   Gui, Jianchao ^a   Yang, Jianping ^a   Yao, Qingqiang ^a   Ji, Yong ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Radionuclides; Rats; Rheumatoid arthritis; Synovitis; Yunke (technetium 99 conjugated with methylene diphosphonate; 99Tc MDP)

Indexed keywords

CHROMIUM PHOSPHATE P 32; INTERLEUKIN 1BETA; MEDRONATE TECHNETIUM TC 99M; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOLOGY; NONHUMAN; RAT; RHEUMATOID ARTHRITIS; SYNOVIUM; TREATMENT OUTCOME;

ANIMALS; ANKLE JOINT; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; CHROMIUM COMPOUNDS; COLLOIDS; COMBINED MODALITY THERAPY; FEMALE; FREUND'S ADJUVANT; INJECTIONS, INTRA-ARTICULAR; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1BETA; PHOSPHATES; RADIOPHARMACEUTICALS; RADIOSURGERY; RATS; RATS, SPRAGUE-DAWLEY; TECHNETIUM TC 99M MEDRONATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36649023496     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04738.x     Document Type: Article

References (38)

1. Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 2005 11 (Suppl. 3 S39 44.
2. Schneider P, Farahati J, Reiners C. Radiosynovectomy in rheumatology, orthopedics, and hemophilia. J. Nucl. Med. 2005 46 (Suppl. 1 S48 54.
3. Qinyang W, Hultenby K, Adlan E, Lindgren JU. Galanin in adjuvant arthritis in the rat. J. Rheumatol. 2004 31 : 302 7.
4. Suresh E, Lambert CM. Combination treatment strategies in early rheumatoid arthritis. Ann. Rheum. Dis. 2005 64 : 1252 6.
5. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. BMJ 2002 325 : 619 23.
6. Yun HR, Bae SC. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Rheumatol. Int. 2005 25 : 9 14.
7. Krug H, Broadwell LK, Berry M, DeLapp R, Palmer RH, Mahowald M. Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis. Clin. Ther. 2000 22 : 40 52.
8. Shi W, Wang YM, Li LS et al. Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis: A six-month randomised study. Clin. Drug Invest. 2004 24 : 89 101.
9. Luza S, Maria E, Segami MI et al. Disease modifying antirheumatic drugs use in patients with rheumatoid arthritis: Experience from a Peruvian referral center. J. Clin. Rheumatol. 2006 12 (Suppl. 4 S48 (Abstract).
10. Blanco M, Puertas E, Marin F. Effect of methotrexate on rheumatoid factor on patients with rheumatoid arthritis. J. Clin. Rheumatol. 2006 12 (Suppl. 4 S50 (Abstract).
11. Wick MC, Lindblad S, Weiss RJ, Klareskog L, van Vollenhoven RF. Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: An observational study. Scand. J. Rheumatol. 2004 33 : 380 4.
12. Eliana GP, Amparo EI, Ferrandiz MZ. Evaluation of infliximab in the treatment of active juvenile rheumatoid arthritis (JRA). J. Clin. Rheumatol. 2006 12 (Suppl. 4 S14 (Abstract).
13. Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea 2005 24 : 742 4.
14. Disla E, Quayum B, Cuppari GG, Pancorbo R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J. Clin. Rheumatol. 2004 10 : 50 2.
15. Cuchacovich M, Ferreira L, Aliste M et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 2004 33 : 228 32.
16. Takeuchi T, Amano K, Kameda H, Abe T. Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases. Allergol. Int. 2005 54 : 191 202.
17. 99Tc-MDP. J. Mod. Clin. Med. Bioeng. 2000 6 : 180 2 (in Chinese).
18. 186rhenium-sulfide: Effect, leakage, and radiation considerations. J. Rheumatol. 2004 31 : 896 901.
19. Huang A, Yu L, Shen L. Effect of technetium-99 conjugated with methylene diphosphonate on IgM-RF, IgG-RF and IgA-RF. J. Huazhong Univ. Sci. Tech. Med. Sci. 2003 23 : 266 8.
20. Simoes SI, Delgado TC, Lopes RM et al. Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in transfersomes. J. Control. Release 2005 103 : 419 34.
21. Soroa VE, del Huerto Velazquez Espeche M, Giannone C et al. Effects of radiosynovectomy with p-32 colloid therapy in hemophilia and rheumatoid arthritis. Cancer Biother. Radiopharm. 2005 20 : 344 8.
22. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate. A superior agent for skyeletal imaging: Comparison with other technetium complexes. J. Nucl. Med. 1975 16 : 744 55.
23. Gudbrandsdottir S, Bliddal H, Petri A et al. Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis. Scand. J. Rheumatol. 2004 33 : 385 8.
24. Pawlik A, Florczak M, Ostanek L, Brzosko M, Brzosko I, Szklarz BG. TNF-alpha -308 promoter polymorphism in patients with rheumatoid arthritis. Scand. J. Rheumatol. 2005 34 : 22 6.
25. Leirisalo-Repo M, Paimela L, Jaattela M, Koskimies S, Repo H. Production of TNF by monocytes of patients with early rheumatoid arthritis is increased. Scand. J. Rheumatol. 1995 24 : 366 71.
26. Edrees AF, Misra SN, Abdou NI. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: Correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin. Exp. Rheumatol. 2005 23 : 469 74.
27. O'Gradaigh D, Ireland D, Bord S, Compston JE. Joint erosion in rheumatoid arthritis: Interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann. Rheum. Dis. 2004 63 : 354 9.
28. Findlay DM, Haynes DR. Mechanisms of bone loss in rheumatoid arthritis. Mod. Rheumatol. 2005 15 : 232 40.
29. Nakamura H, Tanaka H, Yoshino S. Long-term results of multiple synovectomy for patients with refractory rheumatoid arthritis. Effects on disease activity and radiological progression. Clin. Exp. Rheumatol. 2004 22 : 151 7.
30. Karatay S, Erdem T, Yildirim K et al. The effect of individualized diet challenges consisting of allergenic foods on TNF-alpha and IL-1beta levels in patients with rheumatoid arthritis. Rheumatology 2004 43 : 1429 33.
31. Fellinger K, Schmid J. Local therapy of rheumatic diseases. Wien Z. Inn. Med. 1952 33 : 351 63.
32. Clunie G, Lui D, Cullum I, Ell PJ, Edwards JC. Clinical outcome after one year following samarium-153 particulate hydroxyapatite radiation synovectomy. Scand. J. Rheumatol. 1996 25 : 360 6.
33. Turkmen C, Zulflkar B, Taser O et al. Radiosynovectomy in hemophilic synovitis: Correlation of therapeutic response and blood-pool changes. Cancer Biother. Radiopharm. 2005 20 : 363 70.
34. Wang SJ, Lin WY, Chen MN et al. Histologic study of effects of radiation synovectomy with rhenium-188 microsphere. Nucl. Med. Biol. 2001 28 : 727 32.
35. Makela OT, Lammi MJ, Uusitalo H et al. Effect of radiosynovectomy with holmium-166 ferric hydroxide macroaggregate on adult equine cartilage. J. Rheumatol. 2004 31 : 321 8.
36. Nakazato S, Takase H, Yanagihara Y et al. Effect of G-1 column (Adacolumn) therapy in rats with adjuvant arthritis on the migration and immunoreactivity of peripheral and splenic leukocytes. Mod. Rheumatol. 2005 15 : 249 57.
37. Bileviciute-Ljungar I, Saxne T, Spetea M. Anti-inflammatory effects of contralateral administration of the kappa-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis. Rheumatology 2006 45 : 295 302.
38. Zheng YQ, Wei W, Dai M, Zhu L, Jia XY, Wang Y. Interleukin-1 receptor antagonist intervenes in signaling between different types of synoviocytes in rats with adjuvant arthritis. Acta Pharmacol. Sin. 2006 27 : 111 18.